Mutual of America Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Mutual of America Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,370	Closed	-$41K	–	1235
2016 Q3	$41K	Hold	1,370	–	–	﹤0.01%	1200
2016 Q2	$53K	Buy	1,370 +1,237	+930%	+$51.3K	﹤0.01%	1177
2016 Q1	$5K	Hold	133	–	–	﹤0.01%	1224
2015 Q4	$6K	Sell	133 -117	-47%	-$5.8K	﹤0.01%	1240
2015 Q3	$10K	Hold	250	–	–	﹤0.01%	1248
2015 Q2	$13K	Buy	+250	New	+$13.3K	﹤0.01%	1244

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Mutual of America Capital Management's JUNO Position: Q4 2016 in Review

Mutual of America Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 1,370 shares — an estimated $41K sold.

Mutual of America Capital Management first reported a position in JUNO in Q2 2015 and held it in 6 quarters. The position peaked at $53K in Q2 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

Mutual of America Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Mutual of America Capital Management sold 1,370 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $41K.
Mutual of America Capital Management first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
Mutual of America Capital Management's Juno Therapeutics, Inc. position peaked at $53K in Q2 2016.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Mutual of America Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.